In:
World Journal of Surgical Oncology, Springer Science and Business Media LLC, Vol. 20, No. 1 ( 2022-12)
Abstract:
Ovarian clear cell carcinoma (OCCC) is one of the most lethal types of ovarian cancer. Early-stage OCCC can be cured by surgery; however, advanced-stage disease shows poor prognosis due to chemoresistance unlike the more common high-grade serous carcinoma. Methods We explored the differential roles of the Wip1–p38–p53 DNA damage response pathway in respective early- or advanced-stage OCCC by immunohistochemistry of Wip1, phospho-p38, p53, and phospho-p53 from consecutive 143 patients. Results High Wip1 expression correlated with positive p53 ( p =0.011), which in turn correlated with low nuclear phospho-p38 expression ( p =0.0094). In the early stages, positive p53 showed trends toward worse overall survival (OS) ( p =0.062), whereas in the advanced stages, high Wip1 correlated with worse OS ( p =0.0012). The univariate and multivariate analyses of prognostic factors indicated that high Wip1 was significant and independent for worse OS ( p =0.011) in the advanced stages, but not in the early stages. Additionally, high Wip1 showed trends toward shorter treatment-free interval (TFI) in the advanced stages, but not in the early stages ( p =0.083 vs. 0.93). Furthermore, high Wip1 was significantly associated with positive p53 only in the patients with shorter TFI ( 〈 6 months), but not in those with longer TFI (≥6 months) ( p =0.036 vs. 0.34). Conclusions Wip1 appears to play a crucial role for the prognosis of OCCC through chemoresistance specifically in the advanced stages, implicating that Wip1 possibly serves as a reasonable therapeutic target for improving chemoresistance and poor prognosis of advanced-stage OCCC.
Type of Medium:
Online Resource
ISSN:
1477-7819
DOI:
10.1186/s12957-022-02600-7
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2022
detail.hit.zdb_id:
2118383-1
